I et 2- års, randomiseret, dobbeltblindt, non- inferiority, multicenterstudie (BM 16550) var intravenøs injektion af Bonviva 3 mg hver 3. måned mindst ligeså effektivt som oral ibandronsyre 2, 5 mg daglig hos postmenopausale kvinder (1386 kvinder i alderen 55- 80 år) med osteoporose (lumbal BMD T - score under – 2, 5 SD ved baseline).
Bonviva 3 mg intravenous injection, administered every 3 months, was shown to be at least as effective as oral ibandronic acid 2.5 mg daily in a 2-year, randomised, double-blind, multicentre, non- inferiority study (BM16550) of postmenopausal women (1386 women aged 55 - 80) with osteoporosis (lumbar spine BMD T-score below -2.5 SD at baseline).